[144] United Therapeutics Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 8,000 common shares. The shares are to be sold through TD Securities (USA) LLC on NASDAQ with an approximate sale date of 09/09/2025 and an aggregate market value reported as $3,188,374.33. The filing shows the shares were originally acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt. The method of payment is described as shares exercised via a vested option and payment via common shares. The filer reports no securities sold in the past three months and provides the required representation about absence of undisclosed material adverse information.

Positive

• Form 144 filed to disclose the proposed sale of 8,000 common shares, demonstrating regulatory compliance
• Broker identified (TD Securities (USA) LLC) and an approximate sale date (09/09/2025) are provided
• No securities sold in the past three months, simplifying Rule 144 aggregation considerations

Negative

• None.

Insights

Securities Analyst

TL;DR: Filing discloses a small, routine Rule 144 sale—8,000 shares with ~$3.19M aggregate value, to be brokered on NASDAQ.

The Form 144 provides the standard notice for a proposed sale under Rule 144: 8,000 common shares to be executed through TD Securities (USA) LLC with an approximate sale date of 09/09/2025 and an aggregate market value of $3,188,374.33. The shares trace to an acquisition date of 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt and were exercised via a vested option. The filing also notes no sales in the prior three months, which is relevant for Rule 144 aggregation. This appears procedural and consistent with compliance rather than a material corporate event.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements and includes customary representations about material non-public information.

The notice includes the required seller representation that they are not aware of undisclosed material adverse information, and it records the trading plan mechanics (exercise via vested option and payment via common shares). The use of a recognized broker (TD Securities) and the absence of prior three-month sales simplify compliance assessment. No governance concerns or unusual arrangements are evident from the filing text alone.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	8000	3188374.33	45230000	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	09/09/2025	Shares exercised via bested option and payment via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the UTHR Form 144 report?

The filing reports a proposed sale of 8,000 common shares of United Therapeutics (UTHR) via TD Securities with an aggregate market value of $3,188,374.33 and an approximate sale date of 09/09/2025.

Who originally acquired the shares being sold under this Form 144?

The shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt; the filing lists 294,000 as the amount of securities acquired at that time.

Through which broker will the UTHR shares be sold?

The filing names TD Securities (USA) LLC, located at 125 Park Ave, 20th Floor, New York, NY, as the broker handling the proposed sale.

Does the filer report any securities sold in the past three months?

No. The Form 144 states Nothing to Report for securities sold during the past three months.

How were the shares to be sold paid for according to the filing?

The filing states the shares were exercised via a vested option and payment was made via common shares, with a listed payment date of 09/09/2025.